ADAP - Adaptimmune Therapeutics plc (ADAP) CEO Adrian Rawcliffe on Q2 2021 Results - Earnings Call Transcript

Adaptimmune Therapeutics plc (ADAP) Q2 2021 Earnings Conference Call August 09, 2021, 04:30 PM ET Company Participants Juli Miller - IR Adrian Rawcliffe - CEO Helen Tayton-Martin - Co-Founder and Chief Business Officer Elliot Norry - Senior VP and Chief Medical Officer John Lunger - Chief Patient Supply Officer Conference Call Participants Tony Butler - ROTH Capital Marc Frahm - Cowen and Company Kelsey Goodwin - Guggenheim Jonathan Chang - SVB Leerink Mara Goldstein - Mizuho Presentation Operator Good day and thank you for standing by. Welcome to the Adaptimmune Second Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded. I will now like to turn the conference over to Juli Miller, Investor Relations. Please go ahead. Juli Miller Hello, and welcome to Adaptimmune's

For further details see:

Adaptimmune Therapeutics plc (ADAP) CEO Adrian Rawcliffe on Q2 2021 Results - Earnings Call Transcript